# Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients

> **NCT04873349** · NA · COMPLETED · sponsor: **Shimaa M. Abdelgawad** · enrollment: 60 (actual)

## Conditions studied

- Covid19
- COVID-19 Respiratory Infection
- Symptoms and Signs
- COVID-19 Acute Bronchitis
- Disseminated Intravascular Coagulation

## Interventions

- **DIETARY_SUPPLEMENT:** Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)

## Key facts

- **NCT ID:** NCT04873349
- **Lead sponsor:** Shimaa M. Abdelgawad
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-10
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04873349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04873349, "Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04873349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*